Search CTL/CD8+ T-Cell Epitope Database

Found 9 matching records:

Displaying record number 57512

HXB2 Location	Gag(77-85) p17(77-85) DNA(1018..1044)	Gag Epitope Map
Author Location
Epitope	SLYNTVATL	Epitope Alignment
Epitope Name	SLY
Subtype	A, B, C
Species (MHC/HLA)	transgenic mouse(A2)
Immunogen	vaccine
Experimental methods	Flow cytometric T-cell cytokine assay
Keywords	epitope processing, vaccine antigen design

Vaccine Details

Vaccine type	DNA prime with vaccinia boost, polyepitope
Vaccine strain	A clade, B clade, C clade
Vaccine component	Env, Gag, Nef, Pol, Vpr

Notes

• A2 mice were vaccinated with polyepitope vaccines containing 10 A2-restricted epitopes, or subsets of these epitopes, and additional alanine-augmented peptide AQMHEDIISL. Epitopes were chosen from the HIV Database Optimal Epitopes list, and were conserved among clades A, B and C.
• 3 basic constructs C1, C2, C3 were designed: C1 - epitopes linked together without flanking spacer residues; C2 - epitopes linked via spacer sequences to optimize the liberation of determinants by proteasomes; C3 - inserted flanking sequences to optimize TAP transport and, where necesary, additional residues to enhance proteasome epitope liberation. The 3 basic constructs were expressed in 3 vector plasmids: as individual sequences; as fusions with N-terminal ubiquitin (Ub); as fusions with C-terminal Ub.
• The most immunogenic construct contained N-terminal ubiquitin for targeting the polyepitope to the proteasome and included both proteasome liberation and TAP transport optimized spacer sequence that flanked the epitopes.
• Mice immunized with either UbC1 or C3Ub responded to a single peptide - (SLYNTVATL or AQMHEDIISL); responses to 2 peptides (AQMHEDIISL and QMHEDIISL or QMHEDIISL and SLYNTVATL) were generated by nice immunized with C2, C3, UbC2, C1Ub or C2Ub; responses to 3 peptides (AQMHEDIISL, QMHEDIISL, SLYNTVATL) were generated by mice immunized with C1 or UbC3. UbC3 immunization yielded more robust responses.

References

Bazhan2010 S. I. Bazhan, L. I. Karpenko, T. N. Ilyicheva, P. A. Belavin, S. V. Seregin, N. K. Danilyuk, D. V. Antonets, and A. A. Ilyichev. Rational Design Based Synthetic Polyepitope DNA Vaccine for Eliciting HIV-Specific CD8+ T Cell Responses. Mol Immunol, 47(7-8):1507-1515, Apr 2010. PubMed ID: 20189249. Show all entries for this paper.

---

Displaying record number 57625

HXB2 Location	Pol(188-196) RT(33-41) DNA(2646..2672)	Pol Epitope Map
Author Location
Epitope	ALVEICTEM	Epitope Alignment
Epitope Name	ALV
Subtype	B
Species (MHC/HLA)	transgenic mouse(A2)
Immunogen	vaccine
Experimental methods	Flow cytometric T-cell cytokine assay
Keywords	epitope processing, vaccine antigen design

Vaccine Details

Vaccine type	DNA prime with vaccinia boost, polyepitope
Vaccine strain	A clade, B clade, C clade
Vaccine component	Env, Gag, Nef, Pol, Vpr

Notes

• A2 mice were vaccinated with polyepitope vaccines containing 10 A2-restricted epitopes, or subsets of these epitopes, and additional alanine-augmented peptide AQMHEDIISL. Epitopes were chosen from the HIV Database Optimal Epitopes list, and were conserved among clades A, B and C.
• 3 basic constructs C1, C2, C3 were designed: C1 - epitopes linked together without flanking spacer residues; C2 - epitopes linked via spacer sequences to optimize the liberation of determinants by proteasomes; C3 - inserted flanking sequences to optimize TAP transport and, where necesary, additional residues to enhance proteasome epitope liberation. The 3 basic constructs were expressed in 3 vector plasmids: as individual sequences; as fusions with N-terminal ubiquitin (Ub); as fusions with C-terminal Ub.
• The most immunogenic construct contained N-terminal ubiquitin for targeting the polyepitope to the proteasome and included both proteasome liberation and TAP transport optimized spacer sequence that flanked the epitopes.
• This peptide was included in the constructs but did not induce response in any group of immunized animals.

References

Bazhan2010 S. I. Bazhan, L. I. Karpenko, T. N. Ilyicheva, P. A. Belavin, S. V. Seregin, N. K. Danilyuk, D. V. Antonets, and A. A. Ilyichev. Rational Design Based Synthetic Polyepitope DNA Vaccine for Eliciting HIV-Specific CD8+ T Cell Responses. Mol Immunol, 47(7-8):1507-1515, Apr 2010. PubMed ID: 20189249. Show all entries for this paper.

---

Displaying record number 57626

HXB2 Location	Pol(334-342) RT(179-187) DNA(3084..3110)	Pol Epitope Map
Author Location
Epitope	VIYQYMDDL	Epitope Alignment
Epitope Name	VIY
Subtype	A, B, C
Species (MHC/HLA)	transgenic mouse(A2)
Immunogen	vaccine
Experimental methods	Flow cytometric T-cell cytokine assay
Keywords	epitope processing, vaccine antigen design

Vaccine Details

Vaccine type	DNA prime with vaccinia boost, polyepitope
Vaccine strain	A clade, B clade, C clade
Vaccine component	Env, Gag, Nef, Pol, Vpr

Notes

• A2 mice were vaccinated with polyepitope vaccines containing 10 A2-restricted epitopes, or subsets of these epitopes, and additional alanine-augmented peptide AQMHEDIISL. Epitopes were chosen from the HIV Database Optimal Epitopes list, and were conserved among clades A, B and C.
• 3 basic constructs C1, C2, C3 were designed: C1 - epitopes linked together without flanking spacer residues; C2 - epitopes linked via spacer sequences to optimize the liberation of determinants by proteasomes; C3 - inserted flanking sequences to optimize TAP transport and, where necesary, additional residues to enhance proteasome epitope liberation. The 3 basic constructs were expressed in 3 vector plasmids: as individual sequences; as fusions with N-terminal ubiquitin (Ub); as fusions with C-terminal Ub.
• The most immunogenic construct contained N-terminal ubiquitin for targeting the polyepitope to the proteasome and included both proteasome liberation and TAP transport optimized spacer sequence that flanked the epitopes.
• This peptide was included in the constructs but did not induce response in any group of immunized animals.

References

Bazhan2010 S. I. Bazhan, L. I. Karpenko, T. N. Ilyicheva, P. A. Belavin, S. V. Seregin, N. K. Danilyuk, D. V. Antonets, and A. A. Ilyichev. Rational Design Based Synthetic Polyepitope DNA Vaccine for Eliciting HIV-Specific CD8+ T Cell Responses. Mol Immunol, 47(7-8):1507-1515, Apr 2010. PubMed ID: 20189249. Show all entries for this paper.

---

Displaying record number 57627

HXB2 Location	Pol(464-472) RT(309-317) DNA(3474..3500)	Pol Epitope Map
Author Location
Epitope	ILKEPVHGV	Epitope Alignment
Epitope Name	ILK
Subtype	A, B, C
Species (MHC/HLA)	transgenic mouse(A2)
Immunogen	vaccine
Experimental methods	Flow cytometric T-cell cytokine assay
Keywords	epitope processing, vaccine antigen design

Vaccine Details

Vaccine type	DNA prime with vaccinia boost, polyepitope
Vaccine strain	A clade, B clade, C clade
Vaccine component	Env, Gag, Nef, Pol, Vpr

Notes

• A2 mice were vaccinated with polyepitope vaccines containing 10 A2-restricted epitopes, or subsets of these epitopes, and additional alanine-augmented peptide AQMHEDIISL. Epitopes were chosen from the HIV Database Optimal Epitopes list, and were conserved among clades A, B and C.
• 3 basic constructs C1, C2, C3 were designed: C1 - epitopes linked together without flanking spacer residues; C2 - epitopes linked via spacer sequences to optimize the liberation of determinants by proteasomes; C3 - inserted flanking sequences to optimize TAP transport and, where necesary, additional residues to enhance proteasome epitope liberation. The 3 basic constructs were expressed in 3 vector plasmids: as individual sequences; as fusions with N-terminal ubiquitin (Ub); as fusions with C-terminal Ub.
• The most immunogenic construct contained N-terminal ubiquitin for targeting the polyepitope to the proteasome and included both proteasome liberation and TAP transport optimized spacer sequence that flanked the epitopes.
• This peptide was included in the constructs but did not induce response in any group of immunized animals.

References

Bazhan2010 S. I. Bazhan, L. I. Karpenko, T. N. Ilyicheva, P. A. Belavin, S. V. Seregin, N. K. Danilyuk, D. V. Antonets, and A. A. Ilyichev. Rational Design Based Synthetic Polyepitope DNA Vaccine for Eliciting HIV-Specific CD8+ T Cell Responses. Mol Immunol, 47(7-8):1507-1515, Apr 2010. PubMed ID: 20189249. Show all entries for this paper.

---

Displaying record number 57630

HXB2 Location	Vpr(62-70) DNA(5742..5768)	Vpr Epitope Map
Author Location
Epitope	RILQQLLFI	Epitope Alignment
Epitope Name	RIL
Subtype	A, B, C
Species (MHC/HLA)	transgenic mouse(A2)
Immunogen	vaccine
Experimental methods	Flow cytometric T-cell cytokine assay
Keywords	epitope processing, vaccine antigen design

Vaccine Details

Vaccine type	DNA prime with vaccinia boost, polyepitope
Vaccine strain	A clade, B clade, C clade
Vaccine component	Env, Gag, Nef, Pol, Vpr

Notes

• A2 mice were vaccinated with polyepitope vaccines containing 10 A2-restricted epitopes, or subsets of these epitopes, and additional alanine-augmented peptide AQMHEDIISL. Epitopes were chosen from the HIV Database Optimal Epitopes list, and were conserved among clades A, B and C.
• 3 basic constructs C1, C2, C3 were designed: C1 - epitopes linked together without flanking spacer residues; C2 - epitopes linked via spacer sequences to optimize the liberation of determinants by proteasomes; C3 - inserted flanking sequences to optimize TAP transport and, where necesary, additional residues to enhance proteasome epitope liberation. The 3 basic constructs were expressed in 3 vector plasmids: as individual sequences; as fusions with N-terminal ubiquitin (Ub); as fusions with C-terminal Ub.
• The most immunogenic construct contained N-terminal ubiquitin for targeting the polyepitope to the proteasome and included both proteasome liberation and TAP transport optimized spacer sequence that flanked the epitopes.
• This peptide was included in the constructs but did not induce response in any group of immunized animals.

References

Bazhan2010 S. I. Bazhan, L. I. Karpenko, T. N. Ilyicheva, P. A. Belavin, S. V. Seregin, N. K. Danilyuk, D. V. Antonets, and A. A. Ilyichev. Rational Design Based Synthetic Polyepitope DNA Vaccine for Eliciting HIV-Specific CD8+ T Cell Responses. Mol Immunol, 47(7-8):1507-1515, Apr 2010. PubMed ID: 20189249. Show all entries for this paper.

---

Displaying record number 57624

HXB2 Location	gp160(103-111) gp120(103-111) DNA(6531..6557)	gp160 Epitope Map
Author Location
Epitope	QMHEDIISL	Epitope Alignment
Epitope Name	QMH
Subtype	A, B, C
Species (MHC/HLA)	transgenic mouse(A2)
Immunogen	vaccine
Experimental methods	Flow cytometric T-cell cytokine assay
Keywords	epitope processing, vaccine antigen design

Vaccine Details

Vaccine type	DNA prime with vaccinia boost, polyepitope
Vaccine strain	A clade, B clade, C clade
Vaccine component	Env, Gag, Nef, Pol, Vpr

Notes

• A2 mice were vaccinated with polyepitope vaccines containing 10 A2-restricted epitopes, or subsets of these epitopes, and additional alanine-augmented peptide AQMHEDIISL. Epitopes were chosen from the HIV Database Optimal Epitopes list, and were conserved among clades A, B and C.
• 3 basic constructs C1, C2, C3 were designed: C1 - epitopes linked together without flanking spacer residues; C2 - epitopes linked via spacer sequences to optimize the liberation of determinants by proteasomes; C3 - inserted flanking sequences to optimize TAP transport and, where necesary, additional residues to enhance proteasome epitope liberation. The 3 basic constructs were expressed in 3 vector plasmids: as individual sequences; as fusions with N-terminal ubiquitin (Ub); as fusions with C-terminal Ub.
• The most immunogenic construct contained N-terminal ubiquitin for targeting the polyepitope to the proteasome and included both proteasome liberation and TAP transport optimized spacer sequence that flanked the epitopes.
• Mice immunized with either UbC1 or C3Ub responded to a single peptide - (SLYNTVATL or AQMHEDIISL); responses to 2 peptides (AQMHEDIISL and QMHEDIISL or QMHEDIISL and SLYNTVATL) were generated by nice immunized with C2, C3, UbC2, C1Ub or C2Ub; responses to 3 peptides (AQMHEDIISL, QMHEDIISL, SLYNTVATL) were generated by mice immunized with C1 or UbC3. UbC3 immunization yielded more robust responses.

References

Bazhan2010 S. I. Bazhan, L. I. Karpenko, T. N. Ilyicheva, P. A. Belavin, S. V. Seregin, N. K. Danilyuk, D. V. Antonets, and A. A. Ilyichev. Rational Design Based Synthetic Polyepitope DNA Vaccine for Eliciting HIV-Specific CD8+ T Cell Responses. Mol Immunol, 47(7-8):1507-1515, Apr 2010. PubMed ID: 20189249. Show all entries for this paper.

---

Displaying record number 57628

HXB2 Location	gp160(121-129) gp120(121-129) DNA(6585..6611)	gp160 Epitope Map
Author Location
Epitope	KLTPLCVTL	Epitope Alignment
Epitope Name	KLT
Subtype	A, B, C
Species (MHC/HLA)	transgenic mouse(A2)
Immunogen	vaccine
Experimental methods	Flow cytometric T-cell cytokine assay
Keywords	epitope processing, vaccine antigen design

Vaccine Details

Vaccine type	DNA prime with vaccinia boost, polyepitope
Vaccine strain	A clade, B clade, C clade
Vaccine component	Env, Gag, Nef, Pol, Vpr

Notes

• A2 mice were vaccinated with polyepitope vaccines containing 10 A2-restricted epitopes, or subsets of these epitopes, and additional alanine-augmented peptide AQMHEDIISL. Epitopes were chosen from the HIV Database Optimal Epitopes list, and were conserved among clades A, B and C.
• 3 basic constructs C1, C2, C3 were designed: C1 - epitopes linked together without flanking spacer residues; C2 - epitopes linked via spacer sequences to optimize the liberation of determinants by proteasomes; C3 - inserted flanking sequences to optimize TAP transport and, where necesary, additional residues to enhance proteasome epitope liberation. The 3 basic constructs were expressed in 3 vector plasmids: as individual sequences; as fusions with N-terminal ubiquitin (Ub); as fusions with C-terminal Ub.
• The most immunogenic construct contained N-terminal ubiquitin for targeting the polyepitope to the proteasome and included both proteasome liberation and TAP transport optimized spacer sequence that flanked the epitopes.
• This peptide was included in the constructs but did not induce response in any group of immunized animals.

References

Bazhan2010 S. I. Bazhan, L. I. Karpenko, T. N. Ilyicheva, P. A. Belavin, S. V. Seregin, N. K. Danilyuk, D. V. Antonets, and A. A. Ilyichev. Rational Design Based Synthetic Polyepitope DNA Vaccine for Eliciting HIV-Specific CD8+ T Cell Responses. Mol Immunol, 47(7-8):1507-1515, Apr 2010. PubMed ID: 20189249. Show all entries for this paper.

---

Displaying record number 57631

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location
Epitope	RGPGRAFVTI	Epitope Alignment
Epitope Name	RGP
Species (MHC/HLA)	transgenic mouse(A2)
Immunogen	vaccine
Experimental methods	Flow cytometric T-cell cytokine assay
Keywords	epitope processing, vaccine antigen design

Vaccine Details

Vaccine type	DNA prime with vaccinia boost, polyepitope
Vaccine strain	A clade, B clade, C clade
Vaccine component	Env, Gag, Nef, Pol, Vpr

Notes

• A2 mice were vaccinated with polyepitope vaccines containing 10 A2-restricted epitopes, or subsets of these epitopes, and additional alanine-augmented peptide AQMHEDIISL. Epitopes were chosen from the HIV Database Optimal Epitopes list, and were conserved among clades A, B and C.
• 3 basic constructs C1, C2, C3 were designed: C1 - epitopes linked together without flanking spacer residues; C2 - epitopes linked via spacer sequences to optimize the liberation of determinants by proteasomes; C3 - inserted flanking sequences to optimize TAP transport and, where necesary, additional residues to enhance proteasome epitope liberation. The 3 basic constructs were expressed in 3 vector plasmids: as individual sequences; as fusions with N-terminal ubiquitin (Ub); as fusions with C-terminal Ub.
• The most immunogenic construct contained N-terminal ubiquitin for targeting the polyepitope to the proteasome and included both proteasome liberation and TAP transport optimized spacer sequence that flanked the epitopes.
• This peptide was included in the constructs but did not induce response in any group of immunized animals.

References

Bazhan2010 S. I. Bazhan, L. I. Karpenko, T. N. Ilyicheva, P. A. Belavin, S. V. Seregin, N. K. Danilyuk, D. V. Antonets, and A. A. Ilyichev. Rational Design Based Synthetic Polyepitope DNA Vaccine for Eliciting HIV-Specific CD8+ T Cell Responses. Mol Immunol, 47(7-8):1507-1515, Apr 2010. PubMed ID: 20189249. Show all entries for this paper.

---

Displaying record number 57629

HXB2 Location	gp160(770-778) gp41(259-267) DNA(8532..8558)	gp160 Epitope Map
Author Location
Epitope	RLRDLLLIV	Epitope Alignment
Epitope Name	RLR
Subtype	A, B, C
Species (MHC/HLA)	transgenic mouse(A2)
Immunogen	vaccine
Experimental methods	Flow cytometric T-cell cytokine assay
Keywords	epitope processing, vaccine antigen design

Vaccine Details

Vaccine type	DNA prime with vaccinia boost, polyepitope
Vaccine strain	A clade, B clade, C clade
Vaccine component	Env, Gag, Nef, Pol, Vpr

Notes

• A2 mice were vaccinated with polyepitope vaccines containing 10 A2-restricted epitopes, or subsets of these epitopes, and additional alanine-augmented peptide AQMHEDIISL. Epitopes were chosen from the HIV Database Optimal Epitopes list, and were conserved among clades A, B and C.
• 3 basic constructs C1, C2, C3 were designed: C1 - epitopes linked together without flanking spacer residues; C2 - epitopes linked via spacer sequences to optimize the liberation of determinants by proteasomes; C3 - inserted flanking sequences to optimize TAP transport and, where necesary, additional residues to enhance proteasome epitope liberation. The 3 basic constructs were expressed in 3 vector plasmids: as individual sequences; as fusions with N-terminal ubiquitin (Ub); as fusions with C-terminal Ub.
• The most immunogenic construct contained N-terminal ubiquitin for targeting the polyepitope to the proteasome and included both proteasome liberation and TAP transport optimized spacer sequence that flanked the epitopes.
• This peptide was included in the constructs but did not induce response in any group of immunized animals.

References

Bazhan2010 S. I. Bazhan, L. I. Karpenko, T. N. Ilyicheva, P. A. Belavin, S. V. Seregin, N. K. Danilyuk, D. V. Antonets, and A. A. Ilyichev. Rational Design Based Synthetic Polyepitope DNA Vaccine for Eliciting HIV-Specific CD8+ T Cell Responses. Mol Immunol, 47(7-8):1507-1515, Apr 2010. PubMed ID: 20189249. Show all entries for this paper.

---